Aquestive Therapeutics Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2005 | 2006 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -323.1% | – | – | – | – | – | – | – | |
| – | +142.0% | +124.9% | -2.3% | -14.9% | -10.2% | +18.5% | -13.9% | -19.5% | -43.7% | -46.6% | -23.7% | |
| – | – | – | – | – | -76.4% | -6.9% | +3.6% | -35.8% | -38.6% | +164.0% | +7.4% | |
| – | +61.1% | +318.2% | -31.2% | +885.8% | -65.1% | -45.1% | +200.5% | – | – | – | – | |
| – | – | – | – | +1.5% | -239.1% | – | – | – | -116.7% | – | – | |
| – | +22.3% | -71.1% | +111.9% | -11.8% | -63.7% | -22.0% | +76.6% | +176.5% | -60.6% | -84.0% | +253.5% | |
| – | +21.7% | – | -1,188.4% | -11.8% | -63.7% | -22.0% | +76.6% | +176.5% | -60.6% | -84.0% | +253.5% | |
| – | – | – | – | – | – | -96.5% | – | – | – | – | – | |
| – | +70,262.5% | -99.9% | +0.0% | +286,691.7% | -104.1% | -96.5% | -85.9% | -78.6% | +266.7% | – | – | |
| – | -5.6% | -22.3% | -33.3% | -195.4% | – | +70.4% | -100.0% | – | +1,010.5% | -99.9% | +13.0% | |
| – | +159.6% | -78.6% | -22.4% | +1,214.8% | -14.5% | -42.6% | +5.8% | -61.6% | -65.6% | +2,003.5% | +22.8% | |
| – | +1,206.2% | -116.5% | – | +429.0% | -126.1% | – | – | – | – | – | +4.1% | |
| – | – | – | – | -494.4% | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.